Based on these results and on the greater apoptotic effect from inhibitor treatment comparisons using the dual PI3K/mTOR inhibitor NVP-BEZ235 vs. mono BTK inhibitor (Ibrutinib) or PI3Kδ inhibitor (Idelalisib), the group emphasized the possible central role of mRNA translation in CLL survival, depicting its potential as a CLL therapeutic target. The gene discussed is MTOR; the disease is B-cell chronic lymphocytic leukemia.